[CATB] Catabasis Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.75 Change: -0.1 (-2.6%)
Ext. hours: Change: 0 (0%)

chart CATB

Refresh chart

Strongest Trends Summary For CATB

CATB is in the medium-term down -35% below S&P in 2 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities16.89 M Cash From Investing Activities-30 K Cash From Operating Activities-7.23 M Gross Profit
Net Profit-6.5 M Operating Profit-6.36 M Total Assets26.73 M Total Current Assets24.85 M
Total Current Liabilities4.99 M Total Debt9.66 M Total Liabilities13.45 M Total Revenue
Technical Data
High 52 week8.72 Low 52 week0.62 Last close6.05 Last change-1.63%
RSI58.02 Average true range0.47 Beta0.84 Volume118.47 K
Simple moving average 20 days2.14% Simple moving average 50 days7.61% Simple moving average 200 days38.74%
Performance Data
Performance Week2.89% Performance Month21.73% Performance Quart-11.68% Performance Half860.32%
Performance Year326.06% Performance Year-to-date38.44% Volatility daily4.35% Volatility weekly9.73%
Volatility monthly19.94% Volatility yearly69.09% Relative Volume481.52% Average Volume333.3 K
New High New Low

News

2019-03-18 09:02:01 | Rising P/E an Overlooked Criterion: 5 Top Stocks

2019-03-14 18:09:10 | Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT

2019-03-14 08:30:12 | Catabasis CATB Beats Earnings in Q4, Revenues Nil

2019-03-14 08:05:00 | Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress

2019-03-13 08:00:00 | Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference

2019-03-08 09:54:02 | Townsquare TSQ to Report Q4 Earnings: What's in the Cards?

2019-03-07 08:57:01 | Athersys ATHX Q4 Earnings: What's in Store for the Stock?

2019-03-07 08:51:01 | Is a Beat in Store for Catabasis CATB This Earnings Season?

2019-03-06 13:56:33 | Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%

2019-02-28 08:00:00 | Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14

2019-02-19 08:00:00 | Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

2019-02-14 08:00:00 | Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

2019-02-06 09:00:00 | Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 16:01:00 | Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

2019-01-29 07:55:00 | New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-01-15 11:10:39 | Is Catabasis Pharmaceuticals, Inc.’s NASDAQ:CATB CEO Overpaid Relative To Its Peers?

2019-01-14 01:42:06 | Catabasis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

2019-01-11 09:30:02 | Is Catabasis Pharmaceuticals CATB Outperforming Other Medical Stocks This Year?

2019-01-08 08:38:01 | Agenus AGEN Surges: Stock Moves 9.4% Higher

2019-01-04 08:00:00 | Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors

2019-01-03 08:08:00 | Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment

2018-12-31 16:31:00 | Why Canada Goose Holdings, Catabasis Pharmaceuticals, and Globalstar Jumped Today

2018-12-24 08:00:00 | Catabasis Pharmaceuticals Announces Reverse Stock Split

2018-12-18 08:12:00 | Catella Divests Card Issuing Operations in Luxembourg to Advanzia Bank and Completes Strategic Review

2018-12-12 02:22:00 | Catella and Söderberg & Partners in Strategic Partnership

2018-11-28 08:55:00 | Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications

2018-11-27 08:00:00 | Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent CAT-1004 in Duchenne Muscular Dystrophy

2018-11-15 09:26:38 | Does The Catabasis Pharmaceuticals Inc NASDAQ:CATB Share Price Fall With The Market?

2018-11-13 13:21:21 | Edited Transcript of CATB earnings conference call or presentation 13-Nov-18 1:30pm GMT

2018-11-13 08:15:42 | Catabasis Pharmaceuticals: 3Q Earnings Snapshot

2018-11-13 08:05:00 | Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress

2018-11-13 07:45:00 | Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies

2018-11-02 08:00:00 | Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent CAT-1004 in Duchenne Muscular Dystrophy

2018-10-30 08:00:00 | Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13

2018-10-18 08:25:00 | Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth

2018-10-17 14:20:06 | Flagship biotech startup leases space from struggling Catabasis

2018-10-04 09:20:01 | Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

2018-10-03 08:00:00 | Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress

2018-09-25 08:00:00 | Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy

2018-09-19 08:00:00 | Catabasis Pharmaceuticals to Present New Edasalonexent Clinical Results and Phase 3 Trial Design in Duchenne Muscular Dystrophy at the World Muscle Society Congress

2018-09-13 09:13:01 | Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

2018-08-27 07:45:00 | Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-09 09:48:13 | Catabasis Pharmaceuticals: 2Q Earnings Snapshot

2018-08-09 08:05:00 | Catabasis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Reviews Business Progress

2018-08-09 06:30:00 | Catabasis Pharmaceuticals Inc to Host Earnings Call

2018-08-08 08:00:00 | Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

2018-07-26 08:00:00 | Catabasis Pharmaceuticals to Report Second Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, August 9

2018-07-26 08:00:00 | Free Technical Insights on BioPharmX and Three Other Biotech Stocks

2018-07-09 08:00:00 | Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy